This December marks a special milestone: the 10-year anniversary of our collaboration on clinical trials with Adamed Pharma, a leading Polish pharmaceutical manufacturer. Since our first contract for a pharmacokinetic (PK) study, Quinta-Analytica (a Conscio Group company) and Adamed Pharma have partnered on several dozen clinical projects, creating a lasting and impactful relationship that we are immensely proud of.

Over the past decade, the teams at Adamed Pharma and Quinta-Analytica have built a seamless working dynamic, grounded in a commitment and a dedication to bringing safe, reliable medicines to market. This alignment in mission has been key to our sustained cooperation and has helped to contribute to advancing healthcare solutions.

The Head of Clinical department at Quinta, Mrs. Katerina Bilkova confirms:

“Collaborating with Adamed Pharma on PK studies has been a remarkable experience, characterized by their professionalism, precision, and a proactive approach to every project. The quality and organization of the data Adamed Pharma provides for study preparation and regulatory submission are exceptional, ensuring our work together is efficient and impactful from the very start.

Marta Lendo-Sosnowska, Head of Pharmacokinetic Study Team at Adamed Pharma continues:

“Our collaboration with Quinta-Analytica over the past decade has been marked by true partnership. Conducting PK studies is a complex process, and Quinta-Analytica has consistently proven to be a flexible and dependable partner. Their team’s dedication and ability to adapt to our needs have been crucial in navigating the challenges of clinical studies. Clear and open communication is a cornerstone of our partnership. The Quinta team approach has supported us in achieving project milestones with mutual understanding and effective solutions. The commitment to quality and thoroughness, making Quinta-Analytica a partner we can truly rely on.“

As we are glad for this important milestone, Quinta-Analytica looks forward to continuing this journey alongside Adamed Pharma. We are honored to be regarded as a trusted, long-term partner by such a reputable organization and look forward to the future with great optimism and enthusiasm.

Here’s to many more years of successful collaboration, driving innovation, and improving patient outcomes together!

Additional News

  • 25 listopadu 2024

    Expediting Biosimilar development: Streamlining the path from research to market

    On behalf of the Conscio Group, we would like to invite you to a free webinar on the future of the biosimilar pathway to approval, which is now open for registration.

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.